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(www.retroembrace.com). Data from the EMBRACE and 
retroEMBRACE studies show significant correlation between 
dose and outcome for both local control and morbidity 
(bladder, rectum, bowel, vagina).  
While there is currently not international consensus on dose 
planning aims and dose prescription in cervix cancer, the 
dose effect data from the EMBRACE and retroEMBRACE 
studies will change this situation. The upcoming evidence can 
be used to recommend certain dose planning aims and dose 
prescription levels. A new study (EMBRACE II) will for the first 
time implement a prospective dose prescription protocol for 
both target and organs at risk based on clinical outcome data 
from EMBRACE and retroEMBRACE. EMBRACE II will be 
initiated in 2015. 
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Image guided adaptive brachytherapy (IGABT) as part of 
combined radiochemotherapy for locally advanced cervical 
cancer is associated with improved rates of local control with 
simultaneous decrease in morbidity compared to use of 
standard brachytherapy plans in several institutional series.  
Besides tumor control and morbidity, health related quality 
of life (HR-QoL) including patient reported symptoms can 
provide additional important information to evaluate 
treatment efficacy. While clinician-assessed morbidity scales 
are objectively defined, patient reported symptoms provide a 
subjective evaluation without clinical interpretation. Several 
studies have pointed out that there can be considerable 
underreporting of morbidity when patient reported symptoms 
are taken into account, especially for low grade morbidity.  
Comparison of HR-QoL results with age matched normal 
population data can help to point out which symptoms or 
issues are most prevalent during further follow-up after 
treatment. In addition these results can provide patients with 
more detailed information on what to expect during follow-
up.  
Most HR-QoL studies in patients with cervical cancer report 
on a cross-sectional cohort, are not prospective, and have 
included patients with different treatments and 
gynaecological malignancies. Despite these limitations, in 
general radiochemotherapy for locally advanced cervical 
cancer has found to have a considerable impact on HR-QoL 
and patient reported symptoms. During treatment patients 
report more symptoms of fatigue, nausea, appetite loss, 
diarrhea, pain and insomnia, affecting global health status 
and emotional, social and role functioning,although part of 
these symptoms recover over time. Most studies with longer 
follow-up after treatment still find impairments in 
functioning compared to the general population. And some of 
the symptoms may persist years after treatment, like 
diarrhea, urinary frequency and leaking of urine. In addition, 
survivorship studies indicate that sexual symptoms are 
prevalent and sexual functioning is frequently impaired and a 
major source of distress. 
The EMBRACE study (www.embracestudy.dk) investigated the 
introduction of IGABT in a multicentre setting and included 
prospective HR-QoL assessment with EORTC quality of life 
questionnaires. This trial started in 2008 and has included 
over 1200 patients. In an interim EMBRACE report, a 
comparison between CTCAE morbidity and EORTC patient 
reported symptoms confirmed that there was considerable 
underestimation between both endpoints.  
Preliminary EMBRACE HR-QoL results of this study including a 
comparison with age matched norm population data will be 
presented.  
In conclusion, HR-QoL outcomes provide useful additional 
information besides tumor control and clinician-assessed 
morbidity. These outcomes provide useful information when 
counselling patients on what to expect regarding functioning 
and symptoms. Patient reported HR-QoL and symptom 
endpoints can play and important role in future research in 
order to to optimize the therapeutic window, to decrease 
most prevalent symptoms and to increase patient functioning 
and HR-QoL during follow-up.  
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Purpose/Objective: To identify prognostic factors for local 
control in patients treated for locally advanced cervical 
cancer with image guided adaptive brachytherapy, and 
analyse their potential impact on planning aims. 
Materials and Methods: Patients treated with curative intent 
by a combination of external beam radiotherapy and pulsed-
dose rate brachytherapy were selected. Local failure was 
defined as any relapse in the cervix, vagina, parametria, or 
uterus during follow-up. Prognostic factors were selected 
based on log rank tests and then analyzed with a Cox model. 
Dose/effect correlations were performed using the Probit 
model. 
Results: Two hundred and twenty-five patients treated from 
2006 to 2011 were included. According to the FIGO 
classification, 29% were stage IB, 58% stage II, 10% stage III, 
and 3% stage IVA; 95% received concomitant chemotherapy. 
Thirty patients were considered having incomplete response 
or local failure. Among the selected parameters, D90 for HR-
CTV, D90 for IR-CTV, the overall treatment time, the TRAK, 
and the HR-CTV volume appeared significantly correlated 
with local control in univariate analysis. In multivariate 
analysis, overall treatment time > 55 days and HR-CTV 
volume > 30 cm3 appeared independent.  
The Probit analysis showed significant correlations between 
the D90 for both CTVs, and the probability of achieving local 
control (p=0.008 and 0.024). The thresholds to reach to 
warrant a probability of 90% of local control were 85 Gy to 
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the D90 of the HR-CTV and 75 Gy to 90% of the IR-CTV (in 2 
Gy equivalent, α/β=10). To warrant the same local control 
rate, the D90 HR-CTV should be significantly increased in 
stage III-IV tumors, in case of HR-CTV > 30 cm3, excessive 
treatment time, or tumor width at diagnosis > 5 cm (97, 92, 
105, and 92 Gy respectively). Combining the two indepedent 
local prognosis factors: OTT < 56 days and HR-CTV volume < 
30 cm3; OTT > 55 days and HR-CTV volume < 30 cm3, OTT < 
56 days and HR-CTV volume ≥ 30 cm3, and OTT > 55 days and 
HR-CTV volume > 30 cm3, expected local control rates were 
94.3%, 86.6%, 81.7%, and 64.5% respectively, for a planned 
D90 of 85 Gy (p=0.001). 
Conclusions: Overall treatment time and HR-CTV volume 
were independent prognostic factors for local control. The 
planned D90 HR-CTV should be adapted toclinical criteria. 
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Purpose/Objective: To establish dose volume-effect 
relationships for late rectal bleeding in cervix cancer patients 
treated with chemoradiation and MRI-guided adaptive 
brachytherapy within a prospective longitudinal multicenter 
study (EMBRACE study Aim 6). 
Materials and Methods: The first 700 patients included in the 
EMBRACE study were selected. Patients were included prior 
to treatment initiation, and treated with curative intent 
according to institutional protocols. Reporting followed the 
GEC-ESTRO recommendations (D0.1cm3, D2 cm3 OAR). During 
follow-up assessments of morbidity (CTC-AE 3.0) including 
rectal bleeding was conducted 3, 6, 9, 12, 18, 24, 30, 36, 48, 
and 60 months after treatment completion. Late morbidity 
was defined as any event occurring or lasting over 90 days 
after treatment initiation. Patients with missing D2cm3, or 
follow-up less than 90 days from treatment initiation were 
excluded. All doses were converted in 2 Gy equivalent using 
the linear quadratic model and α/β=3 Gy. In case of multiple 
events in a single patient, the one with the highest grade was 
retained for analysis. Dose effect-relationships were assessed 
using log rank tests and the probit model. 
Results: A number of 634 patients fulfilled the inclusion 
criteria. Mean age was 50.6 years (22.2-91.6), and 94.6% of 
the patients received concomitant chemotherapy. The 
median follow-up was 31.5 months (3-66). The mean DICRU, 
D0.1cm3, and D2cm3 were 66.3+/-8.3 Gy, 73.4+/-11.8 Gy, 
and 63.2+/-7.2 Gy, respectively. A total of 223 events was 
reported, 0.35 per patient (0-6). 117 patients had rectal 
bleeding: 87 grade 1 (13.7%), 22 grade 2 (3.5%), and 8 grade 
3 (1.3%). No grade 4 was reported. The mean time to onset 
was 18.0+/-9.5 months. Monitoring of the prevalence of 
grade 1-4 events showed an increasing rate of rectal bleeding 
from 3 months to 2 years (2.5 and 11.6% respectively) 
followed by a trend to recovery (8.1% and 5.6% at 30 and 36 
months). Actuarial cumulative incidences of grade 1-4, 2-4, 
and 3-4 were 24%, 6.8%, and 2% respectively at 3 years. 
Sorting patients according to dose levels (D2cm3 >75 Gy, 70-
75, 65-70, 60-65, 55-60, and 3, for grade 1-4, and 2-4 events 
(p3 and D0.1cm3 and the probability of grade 1-4, 2-4, and 3-
4 events, as well as between DICRU and grade 1-4, 2-4, but 
not for grade 3-4 events. According to this model, a dose 
constraint of 75 Gy for the D2cm3 corresponded to 31%, 9.7%, 
and 3%, of grade 1-4, 2-4, and 3-4 rectal bleeding 
respectively. Decreasing this constraint to 70 Gy would lead 
to probabilities of 25%, 7%, and 2% respectively. 
Conclusions: Significant dose volume-effect correlations 
were found for late rectal bleeding and D0.1cm3 - D2cm3. 
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Purpose/Objective: To report the dosimetric parameters and 
clinical outcome of locally advanced cervical cancer (LACC) 
patients treated with radiochemotherapy (RCT) and MR-
guided pulsed-dose-rate (PDR) adaptive brachytherapy 
(IGABT). 
Materials and Methods: Between 2007 and 2013 one hundred 
thirty-three patients with FIGO stage 1B1 N+ or ≥ 1B2 cervical 
cancer were treated with RCT+IGABT. Treatment schedule 
included a pelvic±paraaortic external beam radiotherapy 
